EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

BCL ‐2 Inhibitor Regulates Number, Function, and Antitumor Immunity of T Cells by Influencing Glycolysis in AML

Xiaohuan Peng iD, Yanhong Li, Futian Tang, Yanling Ma, Jun Bai, Lijuan Li, Liansheng Zhang

Cancer Science · 2025

DOI: 10.1111/cas.70139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Xiaohuan Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Proto-Oncogene Proteins c-bcl-2, Bridged Bicyclo Compounds, Heterocyclic, Glycolysis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Gansu Province, National Natural Science Foundation of China, Medical Research Improvement Project of Lanzhou University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BCL‐2 is one of the key genes in the mitochondrial apoptotic pathway, and BCL‐2 inhibitor Venetoclax (VEN) is the preferred targeted drug for acute myeloid leukemia (AML) patients. However, the effects of VEN on immune cells and antitumor immune responses in AML patients are poorly understood. We first tested the influence of VEN on AML cells and immune cells. Subsequently, we sorted CD4+ T cells and CD8+ T cells from newly diagnosed AML patients in vitro and constructed a peripheral blood mononuclear cell (PBMC)‐humanized AML mouse model to explore the effects of VEN on the T cell number, function, and antitumor immune responses, while actively seeking potential mechanisms. VEN could effectively induce leukemia cell apoptosis and affect the lymphocyte proportion and cytokine levels in the tumor immune microenvironment of AML. T cells of AML patients had apoptosis resistance to VEN, possibly due to their relatively low expression levels of BCL‐2 protein. VEN could regulate the secretory function and activation status of T cells in AML, which mainly manifested in promoting IFN‐γ and Perforin and Granzyme B secretion, upregulating PD‐1 expression, promoting T cell activation, and increasing the proportion of memory T cells. Finally, it was also observed that VEN could enhance T cell‐mediated antitumor immune responses in AML. Mechanistically, VEN modulates the glycolysis pathway of T cells to regulate their number, function, and antitumor immune responses. This research provided a new perspective that molecular‐targeted drugs can promote tumor cell death through a unique immune‐dependent mechanism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteProto-Oncogene Proteins c-bcl-2Bridged Bicyclo Compounds, HeterocyclicGlycolysisSulfonamidesT-LymphocytesAntineoplastic AgentsHumansAnimalsMiceApoptosisTumor MicroenvironmentFemaleMaleCell Line, TumorLymphocyte ActivationCD8-Positive T-LymphocytesProgrammed Cell Death 1 ReceptorMiddle AgedCD4-Positive T-Lymphocytes

Stichwörter der Autor:innen

BCL‐2 inhibitorT cellsacute myeloid leukemiaglycolysistumor immune microenvironmentvenetoclax

Substanzen

Proto-Oncogene Proteins c-bcl-2venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesBCL2 protein, humanAntineoplastic AgentsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
  • Gansu Clinical Medical Research Center of Hematology (National Sub-Center), The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
  • Key Laboratory of the Hematology of Gansu Province, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
  • Key Laboratory of Environment Oncology of Gansu Province, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
  • Department of Tumor Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.

ORCID-Profile: Xiaohuan Peng

Förderung

  • Natural Science Foundation of Gansu Province
  • National Natural Science Foundation of China
  • Medical Research Improvement Project of Lanzhou University
  • Clinical Medical Research Center of Hematological Diseases in Gansu Province
  • Cuiying Technology Innovation Program Project of Lanzhou University Second Hospital
  • Medical Innovation and Development Project of Lanzhou University
  • Gansu Province Key research and development Program Project

Zitieren

APA

Peng, X., Li, Y., Tang, F., Ma, Y., Bai, J., Li, L., & Zhang, L. (2025). BCL ‐2 Inhibitor Regulates Number, Function, and Antitumor Immunity of T Cells by Influencing Glycolysis in AML. Cancer Science. https://doi.org/10.1111/cas.70139

Vancouver

Peng X, Li Y, Tang F, Ma Y, Bai J, Li L, et al. BCL ‐2 Inhibitor Regulates Number, Function, and Antitumor Immunity of T Cells by Influencing Glycolysis in AML. Cancer Science. 2025. doi:10.1111/cas.70139

BibTeX
@article{Peng2025,
  author = {Peng, Xiaohuan and Li, Yanhong and Tang, Futian and Ma, Yanling and Bai, Jun and Li, Lijuan and Zhang, Liansheng},
  title = {BCL ‐2 Inhibitor Regulates Number, Function, and Antitumor Immunity of T Cells by Influencing Glycolysis in AML},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70139}
}
Kostenlos starten →